Farringdon Capital Ltd. Acquires Shares of 2,871 Integer Holdings Co. (NYSE:ITGR)

Farringdon Capital Ltd. bought a new position in shares of Integer Holdings Co. (NYSE:ITGR) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 2,871 shares of the medical equipment provider’s stock, valued at approximately $380,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its position in shares of Integer by 4.4% in the fourth quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider’s stock valued at $220,000 after purchasing an additional 71 shares during the period. Arizona State Retirement System raised its holdings in shares of Integer by 0.9% during the fourth quarter. Arizona State Retirement System now owns 9,732 shares of the medical equipment provider’s stock valued at $1,290,000 after acquiring an additional 84 shares during the last quarter. HighPoint Advisor Group LLC boosted its stake in shares of Integer by 6.4% in the fourth quarter. HighPoint Advisor Group LLC now owns 1,684 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 101 shares during the last quarter. Norden Group LLC raised its stake in Integer by 7.0% in the 4th quarter. Norden Group LLC now owns 1,668 shares of the medical equipment provider’s stock valued at $221,000 after purchasing an additional 109 shares during the last quarter. Finally, Corient Private Wealth LLC lifted its holdings in Integer by 6.4% in the 4th quarter. Corient Private Wealth LLC now owns 1,969 shares of the medical equipment provider’s stock valued at $261,000 after purchasing an additional 118 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Price Performance

NYSE:ITGR opened at $116.99 on Friday. Integer Holdings Co. has a 52 week low of $104.93 and a 52 week high of $146.36. The stock’s fifty day moving average is $122.00 and its two-hundred day moving average is $130.61. The company has a market capitalization of $4.08 billion, a P/E ratio of 34.82, a P/E/G ratio of 1.72 and a beta of 1.09. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). The company had revenue of $449.50 million during the quarter, compared to analysts’ expectations of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. Equities analysts expect that Integer Holdings Co. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Truist Financial reduced their target price on shares of Integer from $163.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, April 11th. Oppenheimer cut Integer from an “outperform” rating to a “market perform” rating in a report on Friday, February 21st. Benchmark increased their price target on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a report on Friday, February 21st. KeyCorp lifted their price objective on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Raymond James started coverage on Integer in a report on Friday, March 28th. They issued an “outperform” rating and a $145.00 target price for the company. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $146.00.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.